Vyne Therapeutics Inc. (VYNE) — 10-Q Filings

10-Q Filings (6)

• VYNE Narrows Losses Amid Clinical Setbacks, Initiates Strategic Review — Nov 6, 2025 Risk: high
  VYNE Therapeutics Inc. reported a net loss of $7.28 million for the three months ended September 30, 2025, a significant improvement from the $12.16 million net
• VYNE Therapeutics Narrows Loss Amid Clinical Setbacks, Strategic Pivot — Aug 14, 2025 Risk: high
  VYNE Therapeutics Inc. reported a net loss of $5.755 million for the three months ended June 30, 2025, an improvement from a net loss of $9.406 million in the p
• VYNE Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  VYNE Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position as of that date.
• VYNE Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  VYNE Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Menlo Therapeutics Inc. and Tigercat Pharma, Inc.
• VYNE Therapeutics Files Q2 2024 10-Q Report — Aug 14, 2024 Risk: medium
  VYNE Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial position and operational activities. Key f
• VYNE Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  VYNE Therapeutics Inc. (VYNE) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. VYNE Therapeutics Inc. filed a 10-Q report for the period ending Marc

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX